AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00161577
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac every 6 hours for 24 hours
Trial: NCT03057041
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mcg of intranasal fentanyl, 50 mcg/ mL in each nostril via mucosal atomizer 15 minutes prior to procedure start
Trial: NCT03057041
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of sterile saline in each nostril via mucosal atomizer 15 minutes prior to procedure start
Trial: NCT01222091
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil administered intravenously at a plasma concentration of 3 ng/mL.
Trial: NCT00978055
Drug: 1: Liothyronine Sodium Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liothyronine Sodium Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting
Trial: NCT00978055
Drug: 2: Cytomel® Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytomel® Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting
Trial: NCT01888536
Drug: Placebo(for Pregabalin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mimic Pregabalin 75mg capsule
Trial: NCT01888536
Drug: Placebo(for Limaprost)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mimic Limaprost tablet
Trial: NCT02039219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.
Trial: NCT02039219
Drug: 10 mg Obeticholic Acid (OCA)
RxNorm normalized name: obeticholic acid 10 MG
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.
Trial: NCT03576066
Drug: ABI-H0731
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ABI-H0731 300 mg tablets orally once daily (QD).
Trial: NCT03576066
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching ABI-0731 tablets orally QD.
Trial: NCT02340247
Drug: Chenodeoxycholic Acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00673205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00695955
Drug: Azilsartan medoxomil with or without add-on chlorthalidone
RxNorm normalized name: azilsartan medoxomil / chlorthalidone Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.
Trial: NCT00695955
Drug: Azilsartan medoxomil with or without add-on hydrochlorothiazide
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
Trial: NCT01562314
Drug: GWP42003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 5 50 mg capsules taken BID
Trial: NCT01562314
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 5 matching capsules taken BID
Trial: NCT05305222
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion
Trial: NCT01190761
Drug: Reminyl 4 mg Tablet, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fed conditions
Trial: NCT02172131
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01190475
Drug: Active treatment with a high dose of BGS649
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01190475
Drug: Active treatment with a low dose of BGS649
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01190475
Drug: Placebo treatment to blind study
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03505788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the placebo group, the patient will receive the standard of care loop diuretics and the placebo
Trial: NCT03834610
Drug: L-arginine 5 gm oral caps
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral L-arginine 5 gm daily for 8 weeks
Trial: NCT03389724
Drug: Capoten®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-I (Capoten®) will be given to patients in the Intervention arm with the start of chemotherapy, twice daily at a dose of 0.5 mg/kg/day (divided over 2 doses)
Trial: NCT01775579
Drug: Glucophage SR tablet 750 mg, Crestor tablet 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01516580
Drug: Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses.
Trial: NCT02030925
Drug: IW-3718
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02030925
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02312999
Drug: Plasmalyte
RxNorm normalized name: PLASMALYTE A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00613002
Drug: testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily transdermal testosterone gel, 300 mcg
Trial: NCT00613002
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily transdermal placebo gel
Trial: NCT01281254
Drug: AMG386 plus PLD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 386 is a first in class investigational anti angiogenic drug that provides potent and selective inhibition of angiopoietins. AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor. Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug. PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
Trial: NCT01281254
Drug: Placebo plus PLD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug.~PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)
Trial: NCT00113399
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01106651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
Trial: NCT00318747
Drug: Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02576041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once a day during 7+3 days run in period
Trial: NCT01535599
Drug: AL-60371, 0.3% Otic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02724917
Drug: APN1125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solid dose form of APN1125
Trial: NCT02724917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match
Trial: NCT01984463
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive an epidural bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
Trial: NCT02959541
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03172325
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg Methotrexate is weekly administered to all the patients.
Trial: NCT03172325
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At least 1 mg Folic acid is daily administered to all the patients.
Trial: NCT03172325
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7.5 mg Prednisolone is daily administered to all the patients.
Trial: NCT02130830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel to mimic topical anesthesia administered in the anal canal at the moment of the anoscopy
Trial: NCT02668770
Drug: MGN1703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group.
Trial: NCT02120300
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg FDC tablet administered orally
Trial: NCT02120300
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg tablet administered orally once daily
Trial: NCT03466099
Drug: KVD001 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal KVD001 Injection
Trial: NCT03208907
Drug: DHA-PQP coadministered with PQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this treatment group, 112 subjects took DHA-PQP for three days and Primaquine for 14 days in the following dose: 0.50 mg/kg/day.
Trial: NCT01114971
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 50 micrograms/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)
Trial: NCT00791479
Drug: Placebo solution and Lifestyle Measures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection once-weekly for up to 12 weeks
Trial: NCT00381511
Drug: low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00115479
Drug: intensive insulin therapy to maintain normoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03119181
Drug: Tymbion Lidocaine/epinephrine solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The external ear canal will be filled with Tymbion drug solution
Trial: NCT00348699
Drug: AFP464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02152371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SQ
Trial: NCT02916641
Drug: Fuzhenghuayu
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01367418
Drug: Patient controlled analgesia (PCA)
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 1 mg/ml
Trial: NCT02052336
Drug: CJ-12420 200mg + Clarithromycin 500mg
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
Trial: NCT02052336
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
Trial: NCT01408550
Drug: NPB-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin
Trial: NCT01408550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline
Trial: NCT00099944
Drug: LAF237 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00634712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01441908
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg or 80mg dose 28 days for 6 month period
Trial: NCT00050531
Drug: Peg-alpha interferon (Peg-Intron)
RxNorm normalized name: PEG-3 alpha-linolenamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-IFN 0.5 mcg/kg each week subcutaneously.
Trial: NCT02099877
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural analgesia will be initiated with 100µg of epidural fentanyl
Trial: NCT03985410
Drug: ETX2514
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT03985410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT00027378
Drug: fluoxetine (Prozac)
RxNorm normalized name: fluoxetine Oral Capsule [Prozac]
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fluoxetine plus Treatment As Usual (TAU); 12 weeks acute phase; plus 9 month naturalistic follow up
Trial: NCT00027378
Drug: Placebo plus Treatment As Usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo plus Treatment as Usual; 12 weeks acute phase; plus 9 month naturalistic follow up
Trial: NCT02321189
Drug: LONGEVINEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: let everyone of the participants oral 1 capsule containing 100 mg LONGEVINEX
Trial: NCT02321189
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: let everyone of the participants oral 1 capsule containing 100 mg placebo
Trial: NCT00771706
Drug: Proton Pump Inhibitor
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PPI arm will consist of a two week course of PPI at a dose 1mg/kg/dose twice daily (minimum dose: 7.5 mg BID; maximum dose: 30 mg BID)
Trial: NCT00771706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
Trial: NCT01895231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01097629
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
Trial: NCT01456195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasiglifam placebo-matching tablets
Trial: NCT01373684
Drug: Nucleos(t)ide analogue
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients are all currently being treated with long-term NA treatment and will continue using these during the study. Dosage depends on which Nucleos(t)ide analogue they are using.
Trial: NCT01851486
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03167112
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin and Irinotecan is followed by Leucovorin (LV) 400 mg/m2 over 2 hours day1
Trial: NCT03167112
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin and Irinotecan and Leucovorin is followed by Fluorouracil (5-FU) 400 mg/m2 bolus day1 and 2,400 mg/m2 46h continuous infusion.
Trial: NCT00956943
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo patch
Trial: NCT01208129
Drug: NAB001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nail lacquer, once daily, 52 weeks
Trial: NCT01208129
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nail lacquer, once daily, 52 weeks
Trial: NCT00247104
Drug: Cranberries - Vaccinium macrocarpon
RxNorm normalized name: Vaccinium macrocarpon whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01667874
Drug: Collatamp G sponge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collatamp G is an antibiotic impregnated sponge
Trial: NCT02566733
Drug: Remiva
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target controlled infusion of remifentanil (generic drug, Remiva™)
Trial: NCT02144272
Drug: LY3114062 SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3114062 administered SC.
Trial: NCT02144272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered SC.
Trial: NCT02144272
Drug: LY3114062 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3114062 administered IV.
Trial: NCT02187276
Drug: cholinesterase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first group received donepezil (5 or 10 mg) the second group received galantamine (16 or 24 mg) The third group received rivastigmine (3 or 4,5 or 6 mg BID) according to the treating physician.
Trial: NCT00611442
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo gelcap, taken at noon the day prior to the colonoscopy
Trial: NCT01587261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactated Ringers solution will be given at a similar volume to what the treatment group will receive
Trial: NCT05055232
Drug: XZP-3621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, dosage ranged from 50 mg to 600 mg, quaque die（QD）with the meal.
Trial: NCT01035437
Drug: HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPPH in D5W, 4.0 mg/m2 infused over 1 hour
Trial: NCT00420004
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-mg and 6-mg tablets
Trial: NCT00420004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04629287
Drug: KPCXM18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route
Trial: NCT01713361
Drug: ISIS-FXIRx Dose #2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
Trial: NCT01713361
Drug: ISIS-FXIRx Dose #3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
Trial: NCT01304069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be given orally placebo twice a day for 7 days prior to the study.
Trial: NCT01304069
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be given orally etoricoxib 120mg once a day for 7 days prior to the study.
Trial: NCT04629287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo,blind,freeze-dried powder,ascending doses，Intravenous route
Trial: NCT02379221
Drug: Injectable
RxNorm normalized name: Injectable Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection
Trial: NCT00584090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo equivalent of 5-10 mg po qd for 1 month
Trial: NCT03341078
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be orally ingested twice daily for 6 weeks.
Trial: NCT01576419
Drug: PG201 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One PG201 tablet and one celecoxib placebo capsule(after breakfast, in 30minutes), One PG201 tablet and one celecoxib placebo capsule(after dinner, in 30minutes)
Trial: NCT00303771
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00303771
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes